Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

2.3K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
2.3K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.6K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

969
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
969
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.

Molecular neurobiology·2026
Same author

Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework.

Biochemical pharmacology·2026
Same author

Genetic alterations in SUPT6H are associated with neurodevelopmental disorders.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

AES-NINDS Epilepsy Benchmarks Area IV: Comorbidities of Epilepsy - Where Are We and Where Will We Go?

Epilepsy currents·2026
Same author

Commonalities in gene expression and methylation changes across two rat models of acquired epilepsy.

Scientific reports·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes.

British journal of pharmacology·2025

Related Experiment Video

Updated: Apr 4, 2026

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.4K

Adenosinergic signaling in epilepsy.

Detlev Boison1

  • 1Robert Stone Dow Neurobiology Laboratories, Legacy Research Institute, Portland, OR 97232, USA.

Neuropharmacology
|September 6, 2015
PubMed
Summary

Despite new drugs, many epilepsies remain untreatable. This review explores how adenosine, an endogenous anticonvulsant, can be therapeutically augmented to control seizures and potentially modify epilepsy development.

Keywords:
AdenosineAdenosine augmentation therapyAdenosine kinaseAstrocytesEpigeneticsEpilepsyEpileptogenesisIctogenesis

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.2K

Related Experiment Videos

Last Updated: Apr 4, 2026

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.4K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.7K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Approximately one-third of epilepsies are refractory to existing antiepileptic drugs (AEDs).
  • Current AEDs primarily suppress neuronal hyperexcitability, not addressing underlying epilepsy development (epileptogenesis).
  • Endogenous seizure control mechanisms, particularly involving adenosine, offer potential therapeutic avenues.

Purpose of the Study:

  • To review the role of adenosinergic mechanisms in seizure expression (ictogenesis) and epilepsy development (epileptogenesis).
  • To highlight novel adenosine-based therapeutic strategies for refractory epilepsy.
  • To explore the potential of adenosine augmentation for disease modification and antiepileptogenesis.

Main Methods:

  • Review of pharmacological, biochemical, enzymatic, and transport mechanisms regulating brain adenosine.
  • Analysis of evidence linking adenosinergic dysregulation to epilepsy and comorbidities.
  • Examination of new findings on adenosine-associated epigenetic mechanisms in epileptogenesis.

Main Results:

  • Dysregulation of adenosinergic mechanisms contributes to seizure activity and epilepsy development.
  • Therapeutic adenosine augmentation shows promise for controlling even drug-refractory seizures.
  • Transient adenosine augmentation may yield lasting epigenetic effects, modifying disease progression.

Conclusions:

  • Adenosine-based therapies represent a promising strategy for improving seizure control in chronic epilepsy.
  • Targeting adenosinergic pathways offers a novel approach to address epileptogenesis and disease modification.
  • Adenosine augmentation may provide disease-modifying and antiepileptogenic outcomes through epigenetic mechanisms.